Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavio Vincenti

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Transplantation|January 16, 2004
Retransplantation in patients with graft loss caused by polyoma virus nephropathyEmilio Ramos, Flavio Vincenti, Wei X Lu, et al.
The New England Journal of Medicine|August 27, 2005
Costimulation blockade with belatacept in renal transplantationFlavio Vincenti, Christian Larsen, Antoine Durrbach, et al.
Transplantation Direct|May 21, 2024
Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST RegistryChristian P Larsen, Flavio Vincenti, Tzuyung D Kou, et al.
Transplantation|October 27, 2005
A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipientsFlavio Vincenti, Robert Mendez, John Curtis, et al.
JAMA|June 6, 2023
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical TrialAjit P Limaye, Klemens Budde, Atul Humar, et al.
Transplantation|October 28, 2010
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockadeAndrew M Posselt, Gregory L Szot, Lynda A Frassetto, et al.
The New England Journal of Medicine|January 28, 2016
Belatacept and Long-Term Outcomes in Kidney TransplantationFlavio Vincenti, Lionel Rostaing, Joseph Grinyo, et al.
Transplantation|March 5, 2011
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)Yves Vanrenterghem, Barbara Bresnahan, Josep Campistol, et al.
Journal of the American Society of Nephrology : JASN|October 28, 2021
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b TrialKlemens Budde, Rohini Prashar, Hermann Haller, et al.
Transplantation Direct|January 26, 2023
Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease PatientsCary M Looney, Aaron Schroeder, Erica Tavares, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Transplantation|January 16, 2004
Retransplantation in patients with graft loss caused by polyoma virus nephropathyEmilio Ramos, Flavio Vincenti, Wei X Lu, et al.
The New England Journal of Medicine|August 27, 2005
Costimulation blockade with belatacept in renal transplantationFlavio Vincenti, Christian Larsen, Antoine Durrbach, et al.
Transplantation Direct|May 21, 2024
Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST RegistryChristian P Larsen, Flavio Vincenti, Tzuyung D Kou, et al.
Transplantation|October 27, 2005
A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipientsFlavio Vincenti, Robert Mendez, John Curtis, et al.
JAMA|June 6, 2023
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical TrialAjit P Limaye, Klemens Budde, Atul Humar, et al.
Transplantation|October 28, 2010
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockadeAndrew M Posselt, Gregory L Szot, Lynda A Frassetto, et al.
The New England Journal of Medicine|January 28, 2016
Belatacept and Long-Term Outcomes in Kidney TransplantationFlavio Vincenti, Lionel Rostaing, Joseph Grinyo, et al.
Transplantation|March 5, 2011
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)Yves Vanrenterghem, Barbara Bresnahan, Josep Campistol, et al.
Journal of the American Society of Nephrology : JASN|October 28, 2021
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b TrialKlemens Budde, Rohini Prashar, Hermann Haller, et al.
Transplantation Direct|January 26, 2023
Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease PatientsCary M Looney, Aaron Schroeder, Erica Tavares, et al.
Pageof 12